Business Context and Reporting Period
Company: Regeneron Pharmaceuticals, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2001
Business Overview: Regeneron is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic drugs for serious medical conditions. The company has not yet generated sales or profits from the commercialization of its own product candidates. Its strategy relies on proprietary technology platforms to develop a pipeline of candidates for obesity, rheumatoid arthritis, cancer, allergies, and asthma.
Key Financial Metrics (Year Ended Dec 31, 2001)
| Metric | 2001 | 2000 |
|---|---|---|
| Total Revenue | $21.97 million | $59.28 million |
| Net Loss | $(76.18) million | $(23.22) million |
| Net Loss Per Share (Basic/Diluted) | $(1.81) | $(0.66) |
| Research & Development Expenses | $91.54 million | $60.56 million |
| Cash & Cash Equivalents | $247.39 million | $30.98 million |
| Total Cash, Equivalents & Marketable Securities | $438.38 million | $154.37 million |
| Long-Term Debt (Convertible Notes) | $200.00 million | $1.47 million |
| Stockholders' Equity | $266.36 million | $182.13 million |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 63% to $22.0 million from $59.3 million in 2000. This was driven by a reduction in contract research and development revenue (down to $12.1 million) and contract manufacturing revenue (down to $9.9 million). The decline in manufacturing revenue was primarily due to timing differences in shipping vaccine intermediates to Merck & Co., Inc.
- Increased Operating Expenses: Total operating expenses rose 27% to $107.7 million. Research and development (R&D) expenses increased 51% to $91.5 million, reflecting higher staffing and the initiation of a Phase III clinical program for AXOKINE and a Phase I study for the IL1 Trap.
- Significant Capital Raise: In October 2001, the company issued $200 million in convertible senior subordinated notes, resulting in $192.7 million in net proceeds. Additionally, a public offering in March/April 2001 raised approximately $156.7 million. These activities significantly increased cash reserves and interest expense.
- Discontinued Programs: Development of BDNF for ALS was discontinued in January 2001 following clinical trial results, leading to a reduction in revenue from the Amgen-Regeneron partnership and Sumitomo Pharmaceuticals.
Guidance, Outlook, and Risks
- Clinical Pipeline Progress:
- AXOKINE (Obesity): Completed enrollment for a pivotal Phase III trial involving approximately 2,000 patients. Preliminary Phase II results showed statistically significant weight loss.
- IL1 Trap (Rheumatoid Arthritis): Reported positive preliminary Phase I results showing dose-dependent improvements. Phase II initiation expected in mid-2002.
- VEGF Trap (Cancer): Initiated Phase I clinical trials in November 2001.
- IL4/IL13 Trap (Asthma/Allergy): Expected to initiate Phase I trials in mid-2002.
- Liquidity Outlook: Management believes existing capital resources ($438.4 million in cash and securities) will enable the company to meet operating needs through at least 2003. Expenses for basic research and clinical development are anticipated to increase by more than 30% in 2002.
- Key Risks:
- Regulatory Approval: No products have been approved for commercial sale; success depends on FDA approval.
- Clinical Trial Failure: Risk of failure or delay in clinical trials due to safety, efficacy, or enrollment issues.
- Collaboration Dependence: Revenue relies heavily on collaborations (e.g., Procter & Gamble, Merck). Termination of these agreements could materially impact funding.
- Intellectual Property: Ongoing legal challenge by Immunex Corporation regarding the scope of Regeneron's European patent for Cytokine Traps.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $438 million cash position against the projected >30% increase in R&D expenses for 2002.
- AXOKINE Phase III Data: Monitor upcoming data releases from the pivotal 2,000-patient trial, as this is the primary driver for future commercialization potential.
- Collaboration Terms: Review the specific terms of the Procter & Gamble agreement (funding through 2005) and the Merck manufacturing contract to assess revenue stability.
- Convertible Note Terms: Examine the conversion price ($30.25) and redemption triggers for the $200 million debt issued in October 2001 to understand potential dilution risks.
- Patent Litigation: Track the status of the Immunex Corporation opposition to the European Cytokine Trap patent.